REG-4basebio Plc: Directorate Change

4BasebioAnnouncement

17/12/2024 07:15

This Announcement contains inside information for the purposes of Article 7
of the Market Abuse Regulation No. 596/2014 as retained as part of UK law by
virtue of the European Union (Withdrawal) Act 2018 as amended ("EUWA") and
as it may be modified from time to time by or under domestic law including,
but not limited to, by the Market Abuse (Amendment) (EU Exit) Regulations
2019/310). Upon the publication of this Announcement, this inside information
is now considered to be in the public domain.

17 December 2024

4basebio PLC

("4basebio" or the "Company")

Directorate Change

17 December 2024 - 4basebio PLC (AIM: 4BB) (“4basebio” or the
“Company”), which develops and commercialises the large scale manufacture
of synthetic DNA as well as nanoparticle delivery solutions, announces the
appointment of Alan Malus as Independent Non-executive Director of the
Company, as of 16 December 2024.

Mr. Alan Joseph Malus, Independent Non-executive Director

Mr. Malus has over 18 years of experience in life sciences and diagnostics,
having most recently served as Corporate Executive Vice President and
President of the Laboratory Products and Services Segment at Thermo Fisher
Scientific. He joined Thermo Fisher in 1998, holding numerous executive
positions including President Analytical Technologies Group, President Lab
Products Group, and President Customer Chanels Group. Prior to this, Mr. Malus
spent nearly 15 years in the automotive industry, working with Ford, Chrysler,
and Textron Inc., where he served as Vice President of Finance.

Since 2023, Mr. Malus has been a Director at Industrial Physics Inc. He also
serves as Director at Azenta Life Sciences.  Previously, he served as a
Director at PHC Holdings Corporation in Japan (2021 to 2022).  

Mr. Malus graduated from the University of Michigan in 1981, starting his
career as a financial analyst at Ford in 1984 and moving to Chrysler in 1986.

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Mr. Alan Joseph Malus (aged
65): 

 Current Directorships    Previous Directorships held in the past five years  
 USA                      Japan                                               
 Azenta Inc.              PHC Holdings Corporation                            
 Industrial Physics, Inc                                                      

Mr. Malus holds no Ordinary Shares, and no options or warrants over Ordinary
Shares. There is no further information regarding Mr. Malus that is required
to be disclosed under the AIM Rules. 

Enquiries

 4basebio PLC Dr. Heikki Lanckriet                                                      +44 (0)1223 967 943  
 Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes  +44 (0)20 7213 0880  
 Joint Broker RBC Capital Markets Rupert Walford / Max Avison / Kathryn Deegan          +44 (0)20 7653 4000  
 Joint Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks                +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved